Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Artivion (DE:CYL)
FRANKFURT:CYL
Holding DE:CYL?
Track your performance easily
CYL Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€15.20 - €28.30
Previous Close€26.75
Volume0.00
Average Volume (3M)162.00
Market Cap
€1.12B
Enterprise Value€1.42B
Total Cash (Recent Filing)$56.17M
Total Debt (Recent Filing)$363.12M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Feb 13, 2025EPS Estimate
-€0.06Last Dividend Ex-Date
Dec 09, 2015Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding41,919,896
10 Day Avg. Volume25
30 Day Avg. Volume162
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)3.68
Price to Sales (P/S)3.05
Price to Cash Flow (P/CF)25.60
P/FCF Ratio12.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.69
Enterprise Value/Gross Profit6.19
Enterprise Value/Ebitda21.96
Forecast
1Y Price Target
€32.00Price Target Upside19.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Artivion News
PremiumCompany Announcements
Artivion’s Q3 2024: Revenue Growth and Strategic Progress
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAORT's third quarter showed a continuation of its double-digit top line and 2x adjusted EBITDA growth profile, with total sales exceeding Street expectations.
Market PotentialThe AMDS product's premarket approval is expected to expand its label to cover the remaining 60% of Type 1 dissections, representing a $150M annual US market opportunity.
Product LaunchThe FDA Humanitarian Device Exemption for the AMDS Hybrid Prosthesis product allows AORT to start U.S. commercialization, representing a major positive for the company.
Bears Say
CybersecurityThe disclosure of a cybersecurity event presents some potential near-term headwinds, but disruptions thus far have not been material.
Market ComparisonThe current valuation does not fully capture the potential upside from possible FDA PMA approvals within its advanced stent graft business.
ValuationThe stock has traded up approximately 50% year-to-date, but the name trades at about 14 times EV/EBITDA, which is lower compared to a peer group trading at around 16 to 17 times.
---
Options Prices
Currently, No data available
---
Ownership Overview
5.00% Insiders
24.45% Mutual Funds
24.30% Other Institutional Investors
23.79% Public Companies and
Individual Investors
CYL FAQ
What was Artivion’s price range in the past 12 months?
Artivion lowest stock price was €15.20 and its highest was €28.30 in the past 12 months.
What is Artivion’s market cap?
Currently, no data Available
When is Artivion’s upcoming earnings report date?
Artivion’s upcoming earnings report date is Feb 13, 2025 which is in 53 days.
How were Artivion’s earnings last quarter?
Artivion released its earnings results on Nov 07, 2024. The company reported -€0.048 earnings per share for the quarter, beating the consensus estimate of -€0.06 by €0.012.
Is Artivion overvalued?
According to Wall Street analysts Artivion’s price is currently Undervalued.
Does Artivion pay dividends?
Artivion pays a Quarterly dividend of €0.028 which represents an annual dividend yield of N/A. See more information on Artivion dividends here
What is Artivion’s EPS estimate?
Artivion’s EPS estimate is -€0.06.
How many shares outstanding does Artivion have?
Artivion has 41,919,895 shares outstanding.
What happened to Artivion’s price movement after its last earnings report?
Artivion reported an EPS of -€0.048 in its last earnings report, beating expectations of -€0.06. Following the earnings report the stock price went down -1.654%.
Which hedge fund is a major shareholder of Artivion?
Among the largest hedge funds holding Artivion’s share is Perceptive Advisors LLC. It holds Artivion’s shares valued at 74M.
---
Artivion Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€32.00 (19.64% Upside)
€32.00 (19.64% Upside)
Blogger Sentiment
Bullish
DE:CYL Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $371.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
59.37%
12-Months-Change
Fundamentals
Return on Equity
-0.30%
Trailing 12-Months
Asset Growth
3.66%
Trailing 12-Months
Company Description
Artivion
CryoLife, Inc. engages in the manufacture, process and distribution of medical devices. It operates through the following segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of BioGlue; JOTEC products, On-X products, CardioGenesis cardiac laser therapy, PerClot and PhotoFix. The Preservation Services segment focuses on external services revenues from the preservation of cardiac and vascular tissues. The company was founded on January 19, 1984 and is headquartered in Kennesaw, GA.
---
CYL Company Deck
---
CYL Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reflects a positive outlook with strong financial performance and significant advancements in regulatory and clinical areas. While there are minor challenges in tissue processing and PerClot revenue, the overall growth strategy and product performance remain robust.Read More>---
CYL Stock 12 Month Forecast
Average Price Target
€32.00
▲(19.64% Upside)
Technical Analysis
Best Analysts Covering CYL
1 Year
1 Year Success Rate
12/16 ratings generated profit
1 Year Average Return
+26.57%
reiterated a buy rating 13 days ago
Copying Frank Takkinen's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +26.57% per trade.
---